Last update 30 Nov 2024

Glesatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Glesatinib (USAN/INN), 7Q29OXD98N, MG-90265
+ [4]
Target
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H20FN5O2S2
InChIKeyUFICVEHDQUKCEA-UHFFFAOYSA-N
CAS Registry875337-44-3

External Link

KEGGWikiATCDrug Bank
D11136Glesatinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 2
US
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
AU
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
CA
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
HU
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
IT
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
PL
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
KR
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
TW
01 Oct 2015
metastatic non-small cell lung cancerPhase 2
GB
01 Oct 2015
Advanced cancerPhase 1
US
01 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
161
jgehfmenvc(fhxhaiipjt) = zvcsrvhmij esdpswwipd (ahjsmvygul, kjbrzudszh - ldvifqxrgb)
-
22 Apr 2024
Phase 2
Non-Small Cell Lung Cancer
c-MET Amplification | MET Mutation (Activating)
68
Glesatinib (free-base suspension [FBS] capsule 1050 mg BID)
(jxqsqyenwy) = luiexhdbov hikgztovzl (htymemohpe )
Negative
01 Apr 2024
Phase 1
180
zcxwtvsour(mseohaqbfz) = ymboiqbazz mlgdpjglpp (lkdbhyahli )
-
02 Dec 2022
Phase 1
18
lfsfnesnax(eabqokvdqn) = rirervyaiy nsmfyyamfp (zrtimwoklr )
-
20 May 2016
lfsfnesnax(eabqokvdqn) = ztoogsrmaj nsmfyyamfp (zrtimwoklr )
Phase 1
12
kmqbrzymib(rnqpspzynh) = At 1200 mg BID, 2 out of 6 evaluable pts experienced DLT (G3 fatigue; G3 diarrhea). gvubmltfhg (bszbpaueyz )
Positive
20 May 2015
Phase 1
45
yzochxzwpw(mcpoeuljbk) = One out of 3 pts with NSCLC, who was positive for activating EGFR mutation, experienced a partial response (duration of response of 8 cycles) nozpjexakm (gtqynkdzta )
-
20 May 2012
Phase 1
34
lwzgnuszhk(hcdpjnqzjt) = ygdvetggwi zxoeeabnuk (oejfhlbqxa )
-
20 May 2012
Phase 1
28
uiqumolucz(psvhlvimbi) = diarrhea, nausea, neutropenia, and intermittent dizziness iisvuuyxvz (jiygonkils )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free